FindTrial
Sign In

Argon laser peripheral iridoplasty (ALPI) versus systemic intraocular pressure lowering medications as the immediate management for acute phacomorphic angle-closure (phacomorphic glaucoma).

Argon laser peripheral iridoplasty (ALPI) versus systemic intraocular pressure lowering medications as the immediate management for acute phacomorphic angle-closure (phacomorphic glaucoma).

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-09000645
Enrollment
Unknown
Registered
2005-09-08
Start date
2005-07-13
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases

Interventions

Two groups:Argon laser peripheral iridoplasty 15 minutes versus drugs

Sponsors

None listed

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Inclusion criteria Age: >18 years, able to give informed consent + co-operate during laser procedure First acute attack of phacomorphic angle closure Intraocular pressure >40 mmHg

Exclusion criteria

Exclusion criteria: Exclusion criteria Treatment received prior to study Corneal opacity preventing laser treatment to peripheral iris Uncooperative patients Single-eyed patients

Design outcomes

Primary

MeasureTime frame
IOP;—

Secondary

MeasureTime frame
Return of corneal clarity Symptoms, particularly pain, nausea & vomiting, and visual acuity Corneal endothelial cell count by specular microscopy - serial Number and types of IOP lowering drugs required Evidence of optic nerve damage at presentation and follow-up Final visual outcome Final angle status by indentation gonioscopy Visual field loss Complications of treatment;—

Countries

China

Contacts

Public ContactProf. Clement CY Tham
www.na@163.com+852 2762 3196

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026